KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Current Deferred Tax Assets: 2012-2015

Historic Current Deferred Tax Assets for Jazz Pharmaceuticals (JAZZ) over the last 3 years, with Sep 2015 value amounting to $50.0 million.

  • Jazz Pharmaceuticals' Current Deferred Tax Assets rose 40.09% to $50.0 million in Q3 2015 from the same period last year, while for Sep 2015 it was $50.0 million, marking a year-over-year increase of 40.09%. This contributed to the annual value of $48.4 million for FY2014, which is 44.11% up from last year.
  • According to the latest figures from Q3 2015, Jazz Pharmaceuticals' Current Deferred Tax Assets is $50.0 million, which was down 1.18% from $50.6 million recorded in Q2 2015.
  • In the past 5 years, Jazz Pharmaceuticals' Current Deferred Tax Assets ranged from a high of $50.8 million in Q1 2015 and a low of $33.6 million during Q4 2013.
  • In the last 3 years, Jazz Pharmaceuticals' Current Deferred Tax Assets had a median value of $46.5 million in 2013 and averaged $43.7 million.
  • The largest annual percentage gain for Jazz Pharmaceuticals' Current Deferred Tax Assets in the last 5 years was 44.11% (2014), contrasted with its biggest fall of 24.47% (2014).
  • Jazz Pharmaceuticals' Current Deferred Tax Assets (Quarterly) stood at $35.8 million in 2012, then dropped by 6.14% to $33.6 million in 2013, then skyrocketed by 44.11% to $48.4 million in 2014, then surged by 40.09% to $50.0 million in 2015.
  • Its last three reported values are $50.0 million in Q3 2015, $50.6 million for Q2 2015, and $50.8 million during Q1 2015.